Anti-hepatitis B virus drugs: Research advances / 国际药学研究杂志

ABSTRACT

The main compounds to treat HBV are nucleoside analogues and interferon, which generally possess the disadvantages of susceptibility to resistance, high cost and serious side effect. In order to overcome the problems above, a large amount of drugs are being developed, including the prodrug of nucleoside analogues(such as besifovir, CMX157 and tenofovir alafenamide), interferon(such as P1101)and antiviral drug based on certain new mechanisms(such as GS-9620, ARC520 and REP-9AC). Among them, the most attention is GS-9620 and REP-9AC, which could against HBV by strengthening body’s immune function. Immunotherapy has been a hot area of antiviral drug research nowadays. In this paper, we review the recent research of a series of new anti-HBV drugs which are undergoing clinical phases.